wire - news in brief
Category
Results 201 - 250 of 356.
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central sub
Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central sub
Subsides d’encouragement de projets de recherche FNS: 26 projets UNIL-CHUV acceptés - News
Subsides d'encouragement de projets de recherche FNS: 26 projets UNIL-CHUV acceptés Lors de la dernière session de printemps 2018, 26 projets de recherche UNIL-CHUV ont été financés par le FNS.
Subsides d'encouragement de projets de recherche FNS: 26 projets UNIL-CHUV acceptés Lors de la dernière session de printemps 2018, 26 projets de recherche UNIL-CHUV ont été financés par le FNS.
ESA ministerial Council sets the stage for the future
Bern, 25.10.2018 - The State Secretary for Education, Research and Innovation Mauro Dell'Ambrogio participated in the ESA's Intermediate Ministerial Meeting in Madrid today.
Bern, 25.10.2018 - The State Secretary for Education, Research and Innovation Mauro Dell'Ambrogio participated in the ESA's Intermediate Ministerial Meeting in Madrid today.
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza First and only single-dose oral medicine approved to treat the flu Xofluza significantly reduced the duration of flu symptom
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza First and only single-dose oral medicine approved to treat the flu Xofluza significantly reduced the duration of flu symptom
To supplement medicines and supplies that are out of stock at the Medical Stores Department (MSD) in Tanzania, Swiss TPH developed the Jazia Prime Vendor System (Jazia PVS).
Media releases, information for representatives of the media Media Relations (E) An interdisciplinary team from the universities of Bern, Oxford and Thessaloniki was awarded a grant of 6.4 million euros from the European Research Council (ERC).
Research into new audio experience resonates at Tinguely Museum in Basel A project funded by the SNSF is investigating the audio phenomena and sound culture associated with radio.
Alcon to develop SMART Suite digital health platform for cataract surgery
SMART Suite by Alcon will drive innovation in ophthalmology delivering personalized and seamless end-to-end care for cataract patients As an open, secure cloud-enabled ecosystem, SMART Suite by Alc
SMART Suite by Alcon will drive innovation in ophthalmology delivering personalized and seamless end-to-end care for cataract patients As an open, secure cloud-enabled ecosystem, SMART Suite by Alc
A new building material developed at Empa is about to be launched on the market: "memory-steel" can not only be used to reinforce new, but also existing concrete structures.
The epigenetics of cartilage repair and regeneration
The European Research Council (ERC) has awarded a prestigious ERC Synergy Grant - perhaps the most competitive funding scheme from ERC - to the research groups of Prof. Filippo Rijli from the
The European Research Council (ERC) has awarded a prestigious ERC Synergy Grant - perhaps the most competitive funding scheme from ERC - to the research groups of Prof. Filippo Rijli from the
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig where other treatments have failed
The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported significan
The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported significan
Roche’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemot
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemot
Novartis COMBI-AD study of Tafinlar + Mekinist continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of patients
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of patients
Roche’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
Entrectinib showed response irrespective of tumour type or spread to the central nervous system (CNS) Data will be submitted to global regulatory authorities, including the US Food and Drug Administr
Entrectinib showed response irrespective of tumour type or spread to the central nervous system (CNS) Data will be submitted to global regulatory authorities, including the US Food and Drug Administr
Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer Tecentriq and nab -paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations Clinically meaningful overall survival improvement in the PD-L1-positive population at this interim analysis Data are being presented at the European Society for Medical Oncology (ESMO) 2
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer Tecentriq and nab -paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations Clinically meaningful overall survival improvement in the PD-L1-positive population at this interim analysis Data are being presented at the European Society for Medical Oncology (ESMO) 2
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer (NSCLC) Clinical findings from ongoing study indicate safety prof
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer (NSCLC) Clinical findings from ongoing study indicate safety prof
Novartis announces presentation of new Lutathera NETTER-1 data
Novartis announces presentation of new Lutathera NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden Lutathera treatment was associated with a
Novartis announces presentation of new Lutathera NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden Lutathera treatment was associated with a
Architect Bernard Tschumi has donated the archives of his Bridge City project - developed for the City of Lausanne in 1988 - to EPFL.
One Health: Working together for human and animal health
Bern, 18.10.2018 - Prevention and early detection are central to effective control of communicable diseases and their vectors, such as mosquitoes.
Bern, 18.10.2018 - Prevention and early detection are central to effective control of communicable diseases and their vectors, such as mosquitoes.
Modifying a virtual environment in just a few clicks
Creating and modifying a virtual reality environment just got a lot easier thanks to software being released today by Imverse, an EPFL spin-off.
Creating and modifying a virtual reality environment just got a lot easier thanks to software being released today by Imverse, an EPFL spin-off.
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx leadership in spondyloarthritis
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) , In rheumatolo
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) , In rheumatolo
Roche’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December Roche tod
Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December Roche tod
Empa and BeAM, a manufacturer of machines for metal 3D printing, are glad to announce an extensive research and development agreement.
EPFL scientists will soon be heading off to Antarctica, where they will spend four months collecting reams of meteorological data at Australia's Davis research station.
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya over Copaxone in patients with relapsing remitting multiple sclerosis
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial Treatment discontinuations were overall more common in the
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial Treatment discontinuations were overall more common in the
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo VOCs are the most common, painful complication of sickle cell disease and the main reas
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo VOCs are the most common, painful complication of sickle cell disease and the main reas
Summit in the field of Additive Manufacturing
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Additive Manufacturing summit
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d